COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH REDUCED EJECTION FRACTION PATIENTS IN INDIAN HEALTHCARE SETTING

被引：0
|
作者：
Gokhale, S. [1 ]
Partha, G. [2 ]
Proudfoot, C. [3 ]
Anand, S. [1 ]
机构：
[1] Novartis Healthcare Pvt Ltd, Mumbai, Maharashtra, India
[2] Novartis Healthcare Pvt Ltd, Hyderabad, India
[3] Novartis Pharma AG, Basel, BS, Switzerland
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC142
引用
收藏
页码：S115 / S115
页数：1
相关论文
共 50 条
  • [41] Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
    Greene, Stephen J.
    Choi, Sujung
    Lippmann, Steven J.
    Mentz, Robert J.
    Greiner, Melissa A.
    Hardy, N. Chantelle
    Hammill, Bradley G.
    Luo, Nancy
    Samsky, Marc D.
    Heidenreich, Paul A.
    Laskey, Warren K.
    Yancy, Clyde W.
    Peterson, Pamela N.
    Curtis, Lesley H.
    Hernandez, Adrian F.
    Fonarow, Gregg C.
    O'Brien, Emily C.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (16):
  • [42] Use of Sacubitril/Valsartan in heart failure with reduced ejection fraction
    吴利强
    冯慧婷
    冯慧娟
    South China Journal of Cardiology, 2019, 20 (04) : 252 - 257
  • [43] Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
    Lee, Ying-Hsiang
    Lin, Po-Lin
    Chiou, Wei-Ru
    Huang, Jin-Long
    Lin, Wen-Yu
    Liao, Chia-Te
    Chung, Fa-Po
    Liang, Huai-Wen
    Hsu, Chien-Yi
    Chang, Hung-Yu
    ESC HEART FAILURE, 2021, 8 (02): : 1204 - 1215
  • [44] COST-EFFECTIVENESS ANALYSIS OF SACUBITRIL/ VALSARTAN IN HEART FAILURE PATIENTS IN EGYPT
    Khalil, A.
    Elsisi, G.
    Mahdy, M. Abdel Meguid
    Mansy, S.
    Farouk, M.
    Seleem, M.
    Nassar, A.
    VALUE IN HEALTH, 2024, 27 (12)
  • [45] Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction
    McCormack, Paul L.
    DRUGS, 2016, 76 (03) : 387 - 396
  • [46] Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction
    Paul L. McCormack
    Drugs, 2016, 76 : 387 - 396
  • [47] Cost-effectiveness of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Bellows, Brandon K.
    Kazi, Dhruv S.
    CIRCULATION, 2020, 142
  • [48] Efficacy and tolerability of sacubitril/valsartan in patients with chronic heart failure and reduced ejection fraction
    Cerciello, Antonio
    Lamaida, Norman
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0G)
  • [49] Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure and Reduced Ejection Fraction Treated with Sacubitril/Valsartan
    Diez-Villanueva, Pablo
    Vicent, Lourdes
    de la Cuerda, Francisco
    Esteban-Fernandez, Alberto
    Gomez-Bueno, Manuel
    de Juan-Baguda, Javier
    Manuel Iniesta, Angel
    Ayesta, Ana
    Rojas-Gonzalez, Antonio
    Bover-Freire, Ramon
    Iglesias, Diego
    Garcia-Aguado, Marcos
    Angel Perea-Egido, Jesus
    Salamanca, Jorge
    Martinez-Selles, Manuel
    CARDIOLOGY, 2020, 145 (05) : 275 - 282
  • [50] Impact of Sacubitril/Valsartan on Lipid Parameters in Patients with Heart Failure with Reduced Ejection Fraction
    Hasan Ali Barman
    Selim Tanyolaç
    Omer Dogan
    Erdem Bal
    Adem Atıcı
    Serhan Özyıldırım
    Zerrin Yiğit
    Clinical Drug Investigation, 2022, 42 : 533 - 540
12345